News

Pipeline Preview

Recent FDA action (through November 2012) related to, H5N1 adjuvanted influenza vaccine, Pasireotide, Digoxin immune fab, Etirinotecan pegol, OBI-1, beclomethasone 17, 21-dipropionate, Regorafenib, Trastuzumab emtansine, A4250, Sildenafil

Individuals with high cholesterol who stay on their statin medications over a 2-year period are healthier than comparable nonadherent individuals, but the overall cost of their care is slightly higher, according to a new study presented at the Academy of Managed Care Pharmacy 2012 Education Conference, in Cincinnati, Ohio, in October.

Recent FDA Approvals (through November 2012) related to (Tofacitinib, Pfizer, Omacetaxine mepesuccinate, Teva, rivaroxaban, Janssen, darunavir)

Topical ivermectin provided a good degree of cure in patients with head lice infection with 1 simple and easy-to-use application, according to a study published in the November 1 issue of the New England Journal of Medicine.

Aubagio (Teriflunomide)

New molecular entity: FDA approved teriflunomide (Aubagio, Genzyme, a Sanofi-Aventis company), a pyrimidine synthesis inhibitor, for the treatment of patients with relapsing forms of multiple sclerosis (MS).

Women who regularly took the analgesics ibuprofen or acetaminophen 2 more days per week had an increased risk of hearing loss, according to a recent study published in a recent issue of the American Journal of Epidemiology.

New combination: FDA approved aclidinium bromide (Tudorza Pressair, Forest) for the long-term maintenance treatment of bronchospasm associated with COPD.